Ivor Douglas
Concepts (598)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Respiration, Artificial | 24 | 2025 | 613 | 3.860 |
Why?
| Sepsis | 20 | 2025 | 574 | 2.880 |
Why?
| Fluid Therapy | 12 | 2025 | 134 | 2.510 |
Why?
| Respiratory Insufficiency | 12 | 2023 | 313 | 2.350 |
Why?
| Critical Care | 19 | 2025 | 553 | 2.290 |
Why?
| Critical Illness | 20 | 2025 | 758 | 2.130 |
Why?
| Intensive Care Units | 24 | 2025 | 738 | 2.100 |
Why?
| Tracheostomy | 5 | 2024 | 121 | 1.780 |
Why?
| Shock, Septic | 11 | 2024 | 209 | 1.600 |
Why?
| Hospital Mortality | 19 | 2024 | 850 | 1.540 |
Why?
| Shock | 3 | 2024 | 92 | 1.460 |
Why?
| Hospitals | 6 | 2023 | 637 | 1.300 |
Why?
| Hypotension | 5 | 2025 | 116 | 1.260 |
Why?
| Pneumonia | 7 | 2023 | 616 | 1.160 |
Why?
| Resuscitation Orders | 3 | 2023 | 46 | 1.030 |
Why?
| Resuscitation | 9 | 2025 | 237 | 0.990 |
Why?
| Multiple Organ Failure | 4 | 2024 | 122 | 0.980 |
Why?
| Humans | 135 | 2025 | 129621 | 0.880 |
Why?
| Patient Readmission | 6 | 2021 | 667 | 0.880 |
Why?
| Vasoconstrictor Agents | 5 | 2023 | 127 | 0.870 |
Why?
| Ultrasonography, Doppler | 1 | 2024 | 118 | 0.850 |
Why?
| Middle Aged | 58 | 2025 | 31150 | 0.830 |
Why?
| Pneumonia, Ventilator-Associated | 2 | 2015 | 49 | 0.820 |
Why?
| Aged | 45 | 2025 | 22099 | 0.810 |
Why?
| Safety-net Providers | 3 | 2023 | 109 | 0.760 |
Why?
| Hospitals, High-Volume | 2 | 2019 | 39 | 0.750 |
Why?
| Hemodynamics | 3 | 2024 | 1089 | 0.740 |
Why?
| Severity of Illness Index | 6 | 2021 | 2742 | 0.720 |
Why?
| Monitoring, Physiologic | 4 | 2024 | 268 | 0.720 |
Why?
| Extracorporeal Membrane Oxygenation | 2 | 2023 | 282 | 0.720 |
Why?
| Retrospective Studies | 31 | 2025 | 14519 | 0.700 |
Why?
| Patient Acceptance of Health Care | 5 | 2021 | 759 | 0.700 |
Why?
| Patient Positioning | 1 | 2021 | 52 | 0.700 |
Why?
| Frailty | 1 | 2023 | 153 | 0.690 |
Why?
| Male | 73 | 2025 | 63674 | 0.690 |
Why?
| Diabetes Insipidus | 1 | 2020 | 7 | 0.680 |
Why?
| Practice Guidelines as Topic | 6 | 2021 | 1501 | 0.660 |
Why?
| Substance Withdrawal Syndrome | 3 | 2021 | 176 | 0.640 |
Why?
| Hospitals, Low-Volume | 1 | 2019 | 22 | 0.630 |
Why?
| Noninvasive Ventilation | 4 | 2025 | 50 | 0.610 |
Why?
| Dyspnea | 2 | 2021 | 242 | 0.590 |
Why?
| Female | 64 | 2025 | 68770 | 0.580 |
Why?
| Adult | 44 | 2025 | 35572 | 0.570 |
Why?
| Delirium | 3 | 2025 | 78 | 0.560 |
Why?
| Pulmonary Disease, Chronic Obstructive | 8 | 2025 | 985 | 0.550 |
Why?
| Diabetes Mellitus | 2 | 2020 | 1001 | 0.550 |
Why?
| Alcoholism | 5 | 2021 | 766 | 0.540 |
Why?
| Ventilator-Induced Lung Injury | 3 | 2018 | 58 | 0.530 |
Why?
| Pulmonary Medicine | 3 | 2015 | 79 | 0.520 |
Why?
| California | 5 | 2022 | 401 | 0.520 |
Why?
| Microbiological Techniques | 1 | 2016 | 30 | 0.510 |
Why?
| Sleep Medicine Specialty | 1 | 2015 | 9 | 0.500 |
Why?
| Acute Lung Injury | 6 | 2023 | 279 | 0.490 |
Why?
| Neoplasms | 3 | 2023 | 2470 | 0.480 |
Why?
| Molecular Diagnostic Techniques | 1 | 2016 | 98 | 0.480 |
Why?
| Health Policy | 4 | 2024 | 353 | 0.470 |
Why?
| Hyperemia | 3 | 2024 | 48 | 0.470 |
Why?
| Ethanol | 2 | 2021 | 589 | 0.460 |
Why?
| Randomized Controlled Trials as Topic | 10 | 2023 | 1367 | 0.460 |
Why?
| Acute Kidney Injury | 7 | 2023 | 790 | 0.450 |
Why?
| Research Design | 9 | 2023 | 1043 | 0.450 |
Why?
| Aged, 80 and over | 13 | 2025 | 7084 | 0.440 |
Why?
| Cohort Studies | 11 | 2023 | 5420 | 0.430 |
Why?
| Renin-Angiotensin System | 2 | 2025 | 82 | 0.430 |
Why?
| Prone Position | 3 | 2021 | 30 | 0.420 |
Why?
| Receptor, EphA2 | 3 | 2018 | 20 | 0.420 |
Why?
| Bronchoalveolar Lavage Fluid | 2 | 2016 | 644 | 0.410 |
Why?
| Cause of Death | 3 | 2015 | 393 | 0.410 |
Why?
| Inpatients | 3 | 2023 | 467 | 0.410 |
Why?
| Laryngoscopes | 2 | 2023 | 34 | 0.400 |
Why?
| Immune Tolerance | 1 | 2015 | 355 | 0.400 |
Why?
| Nicotinic Agonists | 1 | 2014 | 125 | 0.400 |
Why?
| Dual Specificity Phosphatase 1 | 1 | 2012 | 26 | 0.390 |
Why?
| Cross Infection | 5 | 2020 | 218 | 0.390 |
Why?
| Marijuana Smoking | 1 | 2015 | 247 | 0.390 |
Why?
| Hospitalization | 10 | 2025 | 2070 | 0.380 |
Why?
| Apoptosis | 6 | 2014 | 2503 | 0.380 |
Why?
| Tobacco Use Disorder | 1 | 2014 | 237 | 0.370 |
Why?
| Lung | 12 | 2018 | 3931 | 0.370 |
Why?
| Nicotine | 1 | 2014 | 303 | 0.370 |
Why?
| Lipopolysaccharides | 4 | 2017 | 875 | 0.360 |
Why?
| Organ Dysfunction Scores | 2 | 2024 | 44 | 0.360 |
Why?
| Tissue Plasminogen Activator | 2 | 2024 | 222 | 0.360 |
Why?
| Pulmonary Fibrosis | 4 | 2017 | 386 | 0.360 |
Why?
| Immunity, Innate | 1 | 2017 | 804 | 0.360 |
Why?
| Protein C | 5 | 2012 | 47 | 0.350 |
Why?
| Drug Delivery Systems | 1 | 2014 | 336 | 0.350 |
Why?
| Glycosaminoglycans | 3 | 2016 | 84 | 0.350 |
Why?
| Prospective Studies | 12 | 2024 | 7131 | 0.350 |
Why?
| Child Development | 1 | 2015 | 457 | 0.340 |
Why?
| Long-Term Care | 2 | 2022 | 92 | 0.340 |
Why?
| Emergency Service, Hospital | 5 | 2024 | 1902 | 0.330 |
Why?
| Smoking Cessation | 1 | 2014 | 407 | 0.330 |
Why?
| Antipsychotic Agents | 2 | 2024 | 195 | 0.320 |
Why?
| Vena Cava, Inferior | 3 | 2024 | 68 | 0.320 |
Why?
| Comorbidity | 4 | 2022 | 1547 | 0.320 |
Why?
| Metabolic Syndrome | 2 | 2023 | 339 | 0.310 |
Why?
| Ephrin-A1 | 3 | 2018 | 4 | 0.310 |
Why?
| Public Health | 1 | 2014 | 484 | 0.310 |
Why?
| Length of Stay | 6 | 2024 | 1127 | 0.310 |
Why?
| Treatment Outcome | 15 | 2024 | 10226 | 0.310 |
Why?
| United States | 18 | 2024 | 13900 | 0.310 |
Why?
| Lipid A | 2 | 2014 | 29 | 0.300 |
Why?
| Cannabis | 1 | 2015 | 465 | 0.300 |
Why?
| Institutional Practice | 1 | 2008 | 3 | 0.300 |
Why?
| Intubation, Intratracheal | 4 | 2024 | 239 | 0.300 |
Why?
| Societies, Medical | 7 | 2021 | 751 | 0.290 |
Why?
| Betacoronavirus | 2 | 2020 | 249 | 0.290 |
Why?
| Odds Ratio | 6 | 2019 | 1023 | 0.290 |
Why?
| Personnel Staffing and Scheduling | 1 | 2008 | 89 | 0.280 |
Why?
| Biomarkers | 7 | 2023 | 3973 | 0.280 |
Why?
| Pandemics | 4 | 2024 | 1485 | 0.280 |
Why?
| Neutrophils | 3 | 2024 | 1205 | 0.280 |
Why?
| Pulmonary Alveolar Proteinosis | 1 | 2007 | 17 | 0.270 |
Why?
| Integrins | 1 | 2007 | 94 | 0.270 |
Why?
| Anti-Bacterial Agents | 1 | 2017 | 1717 | 0.270 |
Why?
| Neovascularization, Pathologic | 2 | 2007 | 297 | 0.270 |
Why?
| Haloperidol | 3 | 2025 | 32 | 0.270 |
Why?
| MAP Kinase Signaling System | 2 | 2014 | 312 | 0.260 |
Why?
| Patient Admission | 2 | 2023 | 182 | 0.260 |
Why?
| Hyponatremia | 1 | 2006 | 40 | 0.260 |
Why?
| Lung Injury | 3 | 2016 | 210 | 0.260 |
Why?
| Lung Diseases, Obstructive | 1 | 2006 | 46 | 0.260 |
Why?
| Renal Insufficiency, Chronic | 2 | 2024 | 566 | 0.250 |
Why?
| Ultrasonography | 3 | 2024 | 716 | 0.250 |
Why?
| Leukocytes | 1 | 2007 | 304 | 0.250 |
Why?
| Double-Blind Method | 9 | 2024 | 1876 | 0.250 |
Why?
| Pneumonia, Viral | 2 | 2020 | 341 | 0.250 |
Why?
| Coronavirus Infections | 2 | 2020 | 335 | 0.250 |
Why?
| Medicaid | 3 | 2021 | 433 | 0.240 |
Why?
| Laryngoscopy | 2 | 2023 | 97 | 0.240 |
Why?
| Biomedical Research | 3 | 2021 | 638 | 0.240 |
Why?
| Chemokines, CXC | 1 | 2005 | 70 | 0.240 |
Why?
| Bronchi | 1 | 2006 | 247 | 0.240 |
Why?
| Academic Medical Centers | 3 | 2021 | 481 | 0.240 |
Why?
| Regeneration | 1 | 2006 | 180 | 0.230 |
Why?
| Oxazines | 1 | 2024 | 28 | 0.230 |
Why?
| Bronchiectasis | 1 | 2006 | 108 | 0.230 |
Why?
| Bronchiolitis Obliterans | 1 | 2005 | 68 | 0.230 |
Why?
| Adrenal Insufficiency | 2 | 2013 | 32 | 0.230 |
Why?
| Infusions, Intravenous | 5 | 2024 | 399 | 0.230 |
Why?
| Methylprednisolone | 1 | 2005 | 83 | 0.230 |
Why?
| Phagocytosis | 1 | 2006 | 362 | 0.230 |
Why?
| Venous Pressure | 1 | 2024 | 8 | 0.230 |
Why?
| Patient Protection and Affordable Care Act | 2 | 2016 | 100 | 0.220 |
Why?
| Plasminogen | 1 | 2024 | 31 | 0.220 |
Why?
| Morpholines | 1 | 2024 | 122 | 0.220 |
Why?
| Leukocyte Elastase | 1 | 2024 | 74 | 0.220 |
Why?
| Respiratory Mucosa | 1 | 2006 | 307 | 0.220 |
Why?
| Vasopressins | 3 | 2021 | 64 | 0.220 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 2024 | 84 | 0.220 |
Why?
| Anti-Infective Agents | 4 | 2012 | 248 | 0.220 |
Why?
| Cytokines | 7 | 2017 | 2017 | 0.220 |
Why?
| beta Catenin | 1 | 2005 | 223 | 0.220 |
Why?
| Atrial Pressure | 1 | 2023 | 3 | 0.210 |
Why?
| Renal Dialysis | 4 | 2023 | 423 | 0.210 |
Why?
| Hypoxia | 3 | 2024 | 1084 | 0.210 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2023 | 22 | 0.210 |
Why?
| Diterpenes | 2 | 2014 | 32 | 0.210 |
Why?
| Risk Factors | 10 | 2021 | 9763 | 0.210 |
Why?
| Area Under Curve | 3 | 2020 | 304 | 0.210 |
Why?
| Analgesics, Non-Narcotic | 1 | 2024 | 119 | 0.210 |
Why?
| Craniocerebral Trauma | 1 | 2005 | 152 | 0.210 |
Why?
| Hemodynamic Monitoring | 1 | 2022 | 1 | 0.200 |
Why?
| Lung Diseases | 3 | 2016 | 742 | 0.200 |
Why?
| Fibrinolysis | 1 | 2024 | 137 | 0.200 |
Why?
| Thiazoles | 2 | 2024 | 117 | 0.200 |
Why?
| Fibrosis | 1 | 2005 | 520 | 0.200 |
Why?
| Treatment Failure | 6 | 2021 | 340 | 0.200 |
Why?
| Evidence-Based Medicine | 5 | 2016 | 718 | 0.190 |
Why?
| Acetaminophen | 1 | 2024 | 246 | 0.190 |
Why?
| Early Diagnosis | 4 | 2017 | 234 | 0.190 |
Why?
| Transportation | 1 | 2022 | 50 | 0.190 |
Why?
| Clinical Decision-Making | 1 | 2024 | 302 | 0.190 |
Why?
| Vasodilator Agents | 1 | 2023 | 326 | 0.180 |
Why?
| Logistic Models | 7 | 2017 | 1988 | 0.180 |
Why?
| Hydrocortisone | 1 | 2003 | 307 | 0.180 |
Why?
| Central Nervous System Depressants | 1 | 2021 | 82 | 0.180 |
Why?
| Pyridines | 1 | 2024 | 478 | 0.180 |
Why?
| Receptors, Interleukin-6 | 1 | 2021 | 38 | 0.180 |
Why?
| Heart Arrest | 2 | 2021 | 321 | 0.180 |
Why?
| Stroke Volume | 1 | 2024 | 591 | 0.180 |
Why?
| Hospital Charges | 1 | 2020 | 41 | 0.180 |
Why?
| Piperazines | 2 | 2024 | 342 | 0.170 |
Why?
| Health Priorities | 1 | 2020 | 34 | 0.170 |
Why?
| Rib Fractures | 1 | 2020 | 32 | 0.170 |
Why?
| Hydroxychloroquine | 1 | 2020 | 55 | 0.170 |
Why?
| Glucocorticoids | 1 | 2005 | 575 | 0.170 |
Why?
| Community-Acquired Infections | 3 | 2020 | 161 | 0.170 |
Why?
| Internship and Residency | 2 | 2019 | 1052 | 0.170 |
Why?
| Reproducibility of Results | 5 | 2024 | 3083 | 0.170 |
Why?
| Antigens, Differentiation | 1 | 2000 | 81 | 0.170 |
Why?
| Animals | 20 | 2018 | 35360 | 0.160 |
Why?
| Heart Failure | 3 | 2023 | 2149 | 0.160 |
Why?
| Patient Selection | 1 | 2023 | 663 | 0.160 |
Why?
| Cell Proliferation | 2 | 2014 | 2391 | 0.160 |
Why?
| Patient Handoff | 1 | 2019 | 31 | 0.160 |
Why?
| Risk Adjustment | 1 | 2020 | 79 | 0.160 |
Why?
| Cell Adhesion Molecules | 1 | 2000 | 173 | 0.150 |
Why?
| Hospital Costs | 1 | 2019 | 114 | 0.150 |
Why?
| Dopamine Antagonists | 1 | 2018 | 23 | 0.150 |
Why?
| Mice, Inbred C57BL | 9 | 2018 | 5440 | 0.150 |
Why?
| Age Factors | 4 | 2019 | 3144 | 0.150 |
Why?
| Combined Modality Therapy | 2 | 2020 | 1206 | 0.150 |
Why?
| ROC Curve | 1 | 2020 | 503 | 0.150 |
Why?
| Blood Glucose Self-Monitoring | 1 | 2023 | 601 | 0.150 |
Why?
| Antimicrobial Stewardship | 1 | 2020 | 104 | 0.150 |
Why?
| Orthopedic Procedures | 1 | 2020 | 210 | 0.150 |
Why?
| Thrombosis | 1 | 2021 | 343 | 0.140 |
Why?
| Caregivers | 1 | 2025 | 815 | 0.140 |
Why?
| Optometry | 1 | 2017 | 6 | 0.140 |
Why?
| Health Services Accessibility | 4 | 2020 | 902 | 0.140 |
Why?
| Eosinophils | 1 | 2000 | 324 | 0.140 |
Why?
| Platelet Count | 2 | 2014 | 82 | 0.140 |
Why?
| Guideline Adherence | 2 | 2014 | 526 | 0.140 |
Why?
| Cell Adhesion | 4 | 2012 | 452 | 0.140 |
Why?
| Tidal Volume | 2 | 2014 | 84 | 0.140 |
Why?
| Predictive Value of Tests | 4 | 2016 | 1952 | 0.140 |
Why?
| Blood Glucose | 2 | 2023 | 2097 | 0.140 |
Why?
| Lymphocyte Count | 1 | 2017 | 148 | 0.130 |
Why?
| Analysis of Variance | 1 | 2020 | 1288 | 0.130 |
Why?
| Transients and Migrants | 1 | 2017 | 25 | 0.130 |
Why?
| Pyrimidines | 2 | 2024 | 459 | 0.130 |
Why?
| Cystic Fibrosis | 1 | 2006 | 1053 | 0.130 |
Why?
| Mice | 13 | 2017 | 16937 | 0.130 |
Why?
| Tretinoin | 1 | 2017 | 130 | 0.130 |
Why?
| Nephrectomy | 2 | 2008 | 160 | 0.130 |
Why?
| Health Insurance Exchanges | 1 | 2016 | 1 | 0.130 |
Why?
| Delivery of Health Care | 1 | 2023 | 893 | 0.130 |
Why?
| Risk Management | 1 | 2017 | 85 | 0.130 |
Why?
| Continuity of Patient Care | 1 | 2018 | 275 | 0.130 |
Why?
| Clinical Trials as Topic | 1 | 2021 | 1004 | 0.130 |
Why?
| Attitude of Health Personnel | 3 | 2019 | 1095 | 0.130 |
Why?
| Ventricular Function, Right | 1 | 2018 | 276 | 0.130 |
Why?
| Sleep Wake Disorders | 2 | 2017 | 252 | 0.130 |
Why?
| Breath Tests | 1 | 2016 | 91 | 0.130 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 759 | 0.120 |
Why?
| Ventricular Dysfunction, Right | 1 | 2018 | 231 | 0.120 |
Why?
| Burnout, Professional | 1 | 2021 | 408 | 0.120 |
Why?
| Respiratory Tract Diseases | 1 | 2017 | 148 | 0.120 |
Why?
| Research | 1 | 2018 | 416 | 0.120 |
Why?
| Survival Analysis | 4 | 2014 | 1274 | 0.120 |
Why?
| Alcohol Withdrawal Seizures | 1 | 2014 | 1 | 0.120 |
Why?
| Alcohol Withdrawal Delirium | 1 | 2014 | 7 | 0.120 |
Why?
| Marriage | 1 | 2016 | 114 | 0.120 |
Why?
| Staphylococcus aureus | 2 | 2011 | 438 | 0.120 |
Why?
| Bronchoalveolar Lavage | 1 | 2015 | 92 | 0.120 |
Why?
| Automation | 1 | 2015 | 82 | 0.120 |
Why?
| 5-Lipoxygenase-Activating Protein Inhibitors | 1 | 2014 | 1 | 0.120 |
Why?
| 5-Lipoxygenase-Activating Proteins | 1 | 2014 | 4 | 0.120 |
Why?
| Bacteriological Techniques | 1 | 2015 | 69 | 0.120 |
Why?
| Prognosis | 5 | 2021 | 3794 | 0.110 |
Why?
| Risk Assessment | 5 | 2015 | 3240 | 0.110 |
Why?
| Multicenter Studies as Topic | 3 | 2023 | 286 | 0.110 |
Why?
| Patient Care Team | 1 | 2019 | 605 | 0.110 |
Why?
| Fluorobenzenes | 1 | 2014 | 15 | 0.110 |
Why?
| Leukotrienes | 1 | 2014 | 37 | 0.110 |
Why?
| Phenanthrenes | 1 | 2014 | 12 | 0.110 |
Why?
| APACHE | 2 | 2011 | 65 | 0.110 |
Why?
| Physicians | 2 | 2021 | 864 | 0.110 |
Why?
| Quality of Life | 2 | 2024 | 2704 | 0.110 |
Why?
| Education, Medical | 1 | 2017 | 243 | 0.110 |
Why?
| Down-Regulation | 2 | 2017 | 636 | 0.110 |
Why?
| Catheterization, Central Venous | 1 | 2015 | 103 | 0.110 |
Why?
| Potassium | 1 | 2014 | 143 | 0.110 |
Why?
| Alanine Transaminase | 1 | 2014 | 153 | 0.110 |
Why?
| Poverty | 2 | 2016 | 496 | 0.110 |
Why?
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 85 | 0.110 |
Why?
| Kaplan-Meier Estimate | 5 | 2018 | 857 | 0.110 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2000 | 1056 | 0.110 |
Why?
| Laryngeal Masks | 1 | 2013 | 10 | 0.110 |
Why?
| Microscopy | 1 | 2015 | 141 | 0.110 |
Why?
| Quinolines | 1 | 2014 | 156 | 0.100 |
Why?
| Time Factors | 7 | 2023 | 6556 | 0.100 |
Why?
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 1279 | 0.100 |
Why?
| Glycocalyx | 1 | 2012 | 21 | 0.100 |
Why?
| Sensitivity and Specificity | 2 | 2015 | 1838 | 0.100 |
Why?
| Patient Discharge | 1 | 2018 | 857 | 0.100 |
Why?
| Patient-Centered Care | 1 | 2017 | 505 | 0.100 |
Why?
| Supine Position | 1 | 2012 | 38 | 0.100 |
Why?
| Physician-Patient Relations | 1 | 2017 | 537 | 0.100 |
Why?
| Acute Disease | 3 | 2016 | 980 | 0.100 |
Why?
| Cisplatin | 1 | 2014 | 300 | 0.100 |
Why?
| Biomarkers, Pharmacological | 1 | 2012 | 26 | 0.100 |
Why?
| Data Interpretation, Statistical | 2 | 2011 | 335 | 0.100 |
Why?
| Oxygen | 3 | 2023 | 915 | 0.100 |
Why?
| I-kappa B Proteins | 1 | 2012 | 74 | 0.100 |
Why?
| Clinical Alarms | 1 | 2011 | 10 | 0.090 |
Why?
| Insurance, Health | 1 | 2014 | 267 | 0.090 |
Why?
| Data Display | 1 | 2011 | 20 | 0.090 |
Why?
| Health Status | 1 | 2017 | 755 | 0.090 |
Why?
| Follow-Up Studies | 5 | 2024 | 4896 | 0.090 |
Why?
| Endotoxemia | 1 | 2012 | 86 | 0.090 |
Why?
| Adrenergic beta-2 Receptor Agonists | 1 | 2011 | 35 | 0.090 |
Why?
| Indoles | 1 | 2014 | 387 | 0.090 |
Why?
| Albuterol | 1 | 2011 | 103 | 0.090 |
Why?
| Genetic Markers | 1 | 2012 | 338 | 0.090 |
Why?
| Sulfonamides | 1 | 2014 | 496 | 0.090 |
Why?
| Fibrinolytic Agents | 2 | 2024 | 263 | 0.090 |
Why?
| Alcohol-Related Disorders | 1 | 2011 | 118 | 0.080 |
Why?
| Peroxidase | 2 | 2008 | 174 | 0.080 |
Why?
| Stenotrophomonas maltophilia | 1 | 2009 | 2 | 0.080 |
Why?
| Recombinant Proteins | 5 | 2012 | 1304 | 0.080 |
Why?
| Thoracic Diseases | 1 | 2009 | 14 | 0.080 |
Why?
| Decision Making | 1 | 2017 | 850 | 0.080 |
Why?
| Clinical Protocols | 2 | 2012 | 255 | 0.080 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 430 | 0.080 |
Why?
| Interferons | 1 | 2011 | 194 | 0.080 |
Why?
| Survival Rate | 3 | 2015 | 1877 | 0.080 |
Why?
| Wounds and Injuries | 1 | 2016 | 711 | 0.080 |
Why?
| Adrenal Cortex Hormones | 1 | 2013 | 522 | 0.080 |
Why?
| Ligands | 2 | 2023 | 622 | 0.080 |
Why?
| Symptom Assessment | 2 | 2020 | 125 | 0.080 |
Why?
| Gram-Negative Bacterial Infections | 1 | 2009 | 45 | 0.080 |
Why?
| Blotting, Western | 1 | 2012 | 1205 | 0.080 |
Why?
| Cell Movement | 3 | 2011 | 945 | 0.080 |
Why?
| Databases, Factual | 2 | 2016 | 1269 | 0.080 |
Why?
| Disease Models, Animal | 5 | 2018 | 4063 | 0.080 |
Why?
| Polymerase Chain Reaction | 1 | 2012 | 1038 | 0.080 |
Why?
| Confidence Intervals | 1 | 2010 | 317 | 0.080 |
Why?
| Up-Regulation | 1 | 2012 | 840 | 0.080 |
Why?
| Cues | 1 | 2011 | 326 | 0.080 |
Why?
| Age Distribution | 1 | 2010 | 372 | 0.080 |
Why?
| Sex Distribution | 1 | 2010 | 359 | 0.080 |
Why?
| Pancreatitis | 1 | 2009 | 129 | 0.080 |
Why?
| Pneumonia, Bacterial | 1 | 2009 | 115 | 0.080 |
Why?
| Pulmonary Alveoli | 2 | 2012 | 400 | 0.070 |
Why?
| Work Schedule Tolerance | 1 | 2008 | 42 | 0.070 |
Why?
| Models, Statistical | 1 | 2012 | 623 | 0.070 |
Why?
| Clinical Trials, Phase III as Topic | 2 | 2023 | 93 | 0.070 |
Why?
| Healthcare Disparities | 1 | 2014 | 578 | 0.070 |
Why?
| Incidence | 1 | 2014 | 2644 | 0.070 |
Why?
| United Kingdom | 1 | 2008 | 258 | 0.070 |
Why?
| Interleukin-6 | 2 | 2008 | 720 | 0.070 |
Why?
| Mandatory Programs | 1 | 2007 | 15 | 0.070 |
Why?
| Pulmonary Emphysema | 2 | 2007 | 275 | 0.070 |
Why?
| Flavonoids | 1 | 2007 | 78 | 0.070 |
Why?
| Child, Preschool | 2 | 2015 | 10518 | 0.070 |
Why?
| Demeclocycline | 1 | 2006 | 3 | 0.070 |
Why?
| Clinical Competence | 1 | 2014 | 1016 | 0.070 |
Why?
| Mice, Inbred C3H | 1 | 2007 | 273 | 0.070 |
Why?
| Lithium Compounds | 1 | 2006 | 11 | 0.070 |
Why?
| Methicillin Resistance | 1 | 2006 | 18 | 0.070 |
Why?
| Disease Progression | 4 | 2017 | 2635 | 0.070 |
Why?
| Workload | 1 | 2008 | 153 | 0.070 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 151 | 0.070 |
Why?
| Signal Transduction | 4 | 2018 | 4925 | 0.070 |
Why?
| Rats, Sprague-Dawley | 1 | 2012 | 2406 | 0.070 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 1995 | 1052 | 0.070 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2007 | 184 | 0.060 |
Why?
| Intercellular Adhesion Molecule-1 | 2 | 2012 | 135 | 0.060 |
Why?
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2006 | 100 | 0.060 |
Why?
| Diuretics | 1 | 2006 | 76 | 0.060 |
Why?
| Hospitals, Urban | 2 | 2018 | 129 | 0.060 |
Why?
| Hospital Information Systems | 1 | 2006 | 14 | 0.060 |
Why?
| Mesoderm | 1 | 2007 | 137 | 0.060 |
Why?
| Sex Factors | 3 | 2018 | 1968 | 0.060 |
Why?
| History, 20th Century | 2 | 2017 | 291 | 0.060 |
Why?
| Adolescent | 5 | 2025 | 20391 | 0.060 |
Why?
| Asparagine | 1 | 2005 | 30 | 0.060 |
Why?
| Butylated Hydroxytoluene | 1 | 2005 | 38 | 0.060 |
Why?
| Radiography, Thoracic | 1 | 2007 | 168 | 0.060 |
Why?
| Mice, Inbred BALB C | 2 | 2005 | 1245 | 0.060 |
Why?
| Cyclin D1 | 1 | 2005 | 63 | 0.060 |
Why?
| Vocabulary | 1 | 2006 | 46 | 0.060 |
Why?
| Protein Kinase Inhibitors | 2 | 2024 | 891 | 0.060 |
Why?
| Rats | 2 | 2012 | 5499 | 0.060 |
Why?
| Emphysema | 1 | 2006 | 109 | 0.060 |
Why?
| Bronchoscopy | 1 | 2007 | 216 | 0.060 |
Why?
| Heparin | 1 | 2007 | 253 | 0.060 |
Why?
| Cell Line, Transformed | 1 | 2005 | 141 | 0.060 |
Why?
| Medical Order Entry Systems | 1 | 2006 | 43 | 0.060 |
Why?
| Young Adult | 5 | 2025 | 12426 | 0.060 |
Why?
| Occupational Health | 1 | 2008 | 192 | 0.060 |
Why?
| Caspase Inhibitors | 1 | 2005 | 83 | 0.060 |
Why?
| Blood Vessels | 1 | 2007 | 187 | 0.060 |
Why?
| Hypertension, Pulmonary | 2 | 2007 | 1894 | 0.060 |
Why?
| Gene Expression Regulation | 2 | 2012 | 2548 | 0.060 |
Why?
| Angiotensin I | 1 | 2025 | 7 | 0.060 |
Why?
| Venous Thrombosis | 1 | 2007 | 176 | 0.060 |
Why?
| Gene Expression Profiling | 1 | 2012 | 1706 | 0.060 |
Why?
| Ischemia | 1 | 2008 | 406 | 0.060 |
Why?
| Neuromuscular Nondepolarizing Agents | 1 | 2024 | 13 | 0.060 |
Why?
| Necrosis | 1 | 2005 | 232 | 0.060 |
Why?
| Androstanols | 1 | 2024 | 16 | 0.060 |
Why?
| HMGB1 Protein | 1 | 2005 | 48 | 0.060 |
Why?
| Caspases | 1 | 2005 | 245 | 0.060 |
Why?
| Hope | 1 | 2024 | 22 | 0.060 |
Why?
| Pyridazines | 1 | 2024 | 54 | 0.060 |
Why?
| Macrophages | 2 | 2014 | 1480 | 0.060 |
Why?
| Colorado | 4 | 2017 | 4420 | 0.060 |
Why?
| Medicago | 1 | 2023 | 1 | 0.060 |
Why?
| Cadherins | 1 | 2005 | 188 | 0.060 |
Why?
| Diabetic Ketoacidosis | 1 | 2007 | 197 | 0.060 |
Why?
| T-Lymphocyte Subsets | 1 | 2006 | 412 | 0.060 |
Why?
| Renal Replacement Therapy | 1 | 2024 | 87 | 0.060 |
Why?
| Steroids | 2 | 2021 | 158 | 0.050 |
Why?
| Uncertainty | 1 | 2024 | 116 | 0.050 |
Why?
| Practice Patterns, Physicians' | 3 | 2024 | 1266 | 0.050 |
Why?
| Enzyme Inhibitors | 1 | 2007 | 827 | 0.050 |
Why?
| Atrial Function, Right | 1 | 2023 | 12 | 0.050 |
Why?
| Angiotensins | 1 | 2023 | 9 | 0.050 |
Why?
| Multivariate Analysis | 2 | 2017 | 1502 | 0.050 |
Why?
| Collagen | 1 | 2005 | 434 | 0.050 |
Why?
| Heparitin Sulfate | 2 | 2014 | 43 | 0.050 |
Why?
| Mental Health | 2 | 2022 | 686 | 0.050 |
Why?
| Drug Administration Schedule | 2 | 2018 | 769 | 0.050 |
Why?
| Biopsy | 1 | 2007 | 1097 | 0.050 |
Why?
| Inflammatory Bowel Diseases | 1 | 2007 | 320 | 0.050 |
Why?
| Antineoplastic Agents | 1 | 2014 | 2061 | 0.050 |
Why?
| Autoimmune Diseases | 1 | 2006 | 426 | 0.050 |
Why?
| Homeostasis | 1 | 2006 | 611 | 0.050 |
Why?
| Angiotensin II | 1 | 2023 | 95 | 0.050 |
Why?
| Decision Support Techniques | 2 | 2020 | 396 | 0.050 |
Why?
| Anticoagulants | 1 | 2007 | 636 | 0.050 |
Why?
| Diagnosis, Differential | 1 | 2007 | 1434 | 0.050 |
Why?
| Video Recording | 1 | 2023 | 164 | 0.050 |
Why?
| Lung Neoplasms | 1 | 1995 | 2344 | 0.050 |
Why?
| Hemoglobins | 1 | 2024 | 339 | 0.050 |
Why?
| Child | 2 | 2015 | 20882 | 0.050 |
Why?
| p38 Mitogen-Activated Protein Kinases | 2 | 2014 | 274 | 0.050 |
Why?
| Staphylococcal Infections | 1 | 2006 | 393 | 0.050 |
Why?
| Partial Thromboplastin Time | 1 | 2021 | 52 | 0.050 |
Why?
| Creatinine | 2 | 2015 | 491 | 0.050 |
Why?
| Endothelial Cells | 1 | 2007 | 749 | 0.050 |
Why?
| Infant | 1 | 2015 | 9025 | 0.050 |
Why?
| Oligopeptides | 1 | 2023 | 257 | 0.050 |
Why?
| Perioperative Care | 1 | 2022 | 152 | 0.040 |
Why?
| Electrocardiography | 1 | 2024 | 608 | 0.040 |
Why?
| Antibodies | 2 | 2018 | 398 | 0.040 |
Why?
| Peptide Fragments | 1 | 2025 | 692 | 0.040 |
Why?
| Lung Diseases, Interstitial | 1 | 2007 | 616 | 0.040 |
Why?
| Leukotriene C4 | 1 | 2000 | 11 | 0.040 |
Why?
| Hemorrhage | 1 | 2005 | 678 | 0.040 |
Why?
| CD18 Antigens | 1 | 2000 | 26 | 0.040 |
Why?
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2000 | 55 | 0.040 |
Why?
| Drug Resistance, Microbial | 1 | 2020 | 69 | 0.040 |
Why?
| CD11 Antigens | 1 | 2000 | 30 | 0.040 |
Why?
| Chronic Disease | 1 | 2006 | 1720 | 0.040 |
Why?
| Glasgow Coma Scale | 1 | 2020 | 167 | 0.040 |
Why?
| Costs and Cost Analysis | 1 | 2020 | 201 | 0.040 |
Why?
| Epithelial Cells | 1 | 2005 | 1065 | 0.040 |
Why?
| Hospitals, University | 1 | 2019 | 179 | 0.040 |
Why?
| Needs Assessment | 1 | 2021 | 360 | 0.040 |
Why?
| Flow Cytometry | 2 | 2017 | 1156 | 0.040 |
Why?
| Aftercare | 1 | 2001 | 205 | 0.040 |
Why?
| Smoking | 1 | 2006 | 1501 | 0.040 |
Why?
| Oxidative Stress | 1 | 2005 | 1269 | 0.040 |
Why?
| NF-kappa B | 2 | 2018 | 653 | 0.040 |
Why?
| Infection Control | 1 | 2020 | 140 | 0.040 |
Why?
| Surveys and Questionnaires | 3 | 2021 | 5401 | 0.040 |
Why?
| Algorithms | 1 | 2006 | 1622 | 0.040 |
Why?
| Adjuvants, Immunologic | 1 | 2000 | 221 | 0.040 |
Why?
| Injury Severity Score | 1 | 2020 | 509 | 0.040 |
Why?
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2018 | 4 | 0.040 |
Why?
| Linear Models | 1 | 2020 | 819 | 0.040 |
Why?
| Mice, Knockout | 3 | 2012 | 2871 | 0.040 |
Why?
| T-Lymphocytes | 1 | 2006 | 1928 | 0.040 |
Why?
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2018 | 37 | 0.040 |
Why?
| Trauma Centers | 1 | 2020 | 402 | 0.040 |
Why?
| Victoria | 1 | 2017 | 16 | 0.040 |
Why?
| Mortality | 1 | 2019 | 307 | 0.030 |
Why?
| History, 17th Century | 1 | 2017 | 14 | 0.030 |
Why?
| Family | 1 | 2022 | 657 | 0.030 |
Why?
| Antigens, CD | 1 | 2000 | 489 | 0.030 |
Why?
| History, 16th Century | 1 | 2017 | 14 | 0.030 |
Why?
| History, 15th Century | 1 | 2017 | 11 | 0.030 |
Why?
| United Arab Emirates | 1 | 2017 | 7 | 0.030 |
Why?
| History, Ancient | 1 | 2017 | 52 | 0.030 |
Why?
| History, Medieval | 1 | 2017 | 44 | 0.030 |
Why?
| Critical Care Outcomes | 1 | 2016 | 12 | 0.030 |
Why?
| Drug Therapy, Combination | 2 | 2012 | 1040 | 0.030 |
Why?
| Recovery of Function | 1 | 2021 | 642 | 0.030 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2025 | 825 | 0.030 |
Why?
| History, 21st Century | 1 | 2017 | 183 | 0.030 |
Why?
| Cross-Sectional Studies | 2 | 2021 | 5066 | 0.030 |
Why?
| Trauma Severity Indices | 1 | 2016 | 104 | 0.030 |
Why?
| Probability | 1 | 2017 | 306 | 0.030 |
Why?
| Lymphocyte Activation | 1 | 2000 | 1106 | 0.030 |
Why?
| Refugees | 1 | 2017 | 66 | 0.030 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2018 | 431 | 0.030 |
Why?
| Uteroglobin | 1 | 2014 | 23 | 0.030 |
Why?
| Anxiety | 1 | 2022 | 965 | 0.030 |
Why?
| Chemokine CXCL2 | 1 | 2014 | 43 | 0.030 |
Why?
| Cost-Benefit Analysis | 1 | 2017 | 569 | 0.030 |
Why?
| Arachidonate 5-Lipoxygenase | 1 | 2014 | 42 | 0.030 |
Why?
| Pilot Projects | 1 | 2019 | 1587 | 0.030 |
Why?
| Rosuvastatin Calcium | 1 | 2014 | 20 | 0.030 |
Why?
| Nitrites | 1 | 2014 | 83 | 0.030 |
Why?
| MAP Kinase Kinase 4 | 1 | 2014 | 28 | 0.030 |
Why?
| Risk | 1 | 2017 | 854 | 0.030 |
Why?
| Creatine Kinase | 1 | 2014 | 73 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2018 | 1214 | 0.030 |
Why?
| Epoxy Compounds | 1 | 2014 | 32 | 0.030 |
Why?
| Nitrates | 1 | 2014 | 89 | 0.030 |
Why?
| Quality Indicators, Health Care | 1 | 2017 | 298 | 0.030 |
Why?
| Chondroitin Sulfates | 1 | 2014 | 35 | 0.030 |
Why?
| Toll-Like Receptor 2 | 1 | 2014 | 113 | 0.030 |
Why?
| Kidney Function Tests | 1 | 2014 | 152 | 0.030 |
Why?
| Manikins | 1 | 2013 | 24 | 0.030 |
Why?
| Leukocyte Count | 1 | 2014 | 326 | 0.030 |
Why?
| Liver Failure | 1 | 2014 | 91 | 0.030 |
Why?
| Bronchial Spasm | 1 | 2013 | 6 | 0.030 |
Why?
| Cryptogenic Organizing Pneumonia | 1 | 2013 | 19 | 0.030 |
Why?
| Quality Improvement | 1 | 2021 | 1101 | 0.030 |
Why?
| Contraindications | 1 | 2013 | 90 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2015 | 423 | 0.030 |
Why?
| Mass Spectrometry | 1 | 2016 | 716 | 0.030 |
Why?
| Depression | 1 | 2022 | 1307 | 0.030 |
Why?
| Anesthesiology | 1 | 2013 | 45 | 0.030 |
Why?
| Glucuronidase | 1 | 2012 | 44 | 0.020 |
Why?
| Protein C Deficiency | 1 | 2012 | 8 | 0.020 |
Why?
| Connective Tissue Diseases | 1 | 2013 | 82 | 0.020 |
Why?
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2012 | 85 | 0.020 |
Why?
| Knowledge Bases | 1 | 2012 | 24 | 0.020 |
Why?
| Cells, Cultured | 1 | 2000 | 4083 | 0.020 |
Why?
| Intestinal Perforation | 1 | 2012 | 45 | 0.020 |
Why?
| Toll-Like Receptor 4 | 1 | 2014 | 263 | 0.020 |
Why?
| Triage | 1 | 2014 | 206 | 0.020 |
Why?
| Renal Insufficiency | 1 | 2014 | 149 | 0.020 |
Why?
| Tandem Mass Spectrometry | 1 | 2015 | 524 | 0.020 |
Why?
| Quality of Health Care | 1 | 2017 | 608 | 0.020 |
Why?
| Disease Management | 1 | 2016 | 589 | 0.020 |
Why?
| Quality Assurance, Health Care | 1 | 2014 | 318 | 0.020 |
Why?
| Endothelium | 1 | 2012 | 121 | 0.020 |
Why?
| Water-Electrolyte Balance | 1 | 2011 | 34 | 0.020 |
Why?
| Adoptive Transfer | 1 | 2012 | 218 | 0.020 |
Why?
| Epistasis, Genetic | 1 | 2012 | 70 | 0.020 |
Why?
| General Surgery | 1 | 2013 | 152 | 0.020 |
Why?
| Cross-Over Studies | 1 | 2013 | 521 | 0.020 |
Why?
| Cell Survival | 1 | 2014 | 1086 | 0.020 |
Why?
| Microbial Viability | 1 | 2011 | 84 | 0.020 |
Why?
| Superoxides | 1 | 2011 | 201 | 0.020 |
Why?
| Internal Medicine | 1 | 2013 | 248 | 0.020 |
Why?
| Enzyme Activation | 1 | 2012 | 811 | 0.020 |
Why?
| Interleukin-8 | 1 | 2011 | 262 | 0.020 |
Why?
| Viruses | 1 | 2011 | 100 | 0.020 |
Why?
| Cell Separation | 1 | 2011 | 316 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2017 | 2716 | 0.020 |
Why?
| Single-Payer System | 1 | 2009 | 2 | 0.020 |
Why?
| Arthroplasty, Replacement, Knee | 1 | 2014 | 305 | 0.020 |
Why?
| Species Specificity | 1 | 2011 | 575 | 0.020 |
Why?
| Disease-Free Survival | 1 | 2011 | 648 | 0.020 |
Why?
| Administration, Inhalation | 1 | 2011 | 666 | 0.020 |
Why?
| Cell Death | 1 | 2011 | 354 | 0.020 |
Why?
| Survivors | 1 | 2013 | 464 | 0.020 |
Why?
| Information Dissemination | 1 | 2011 | 205 | 0.020 |
Why?
| Nitric Oxide | 1 | 2014 | 902 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 833 | 0.020 |
Why?
| Advisory Committees | 1 | 2010 | 216 | 0.020 |
Why?
| Case-Control Studies | 1 | 2016 | 3381 | 0.020 |
Why?
| Self Report | 1 | 2013 | 799 | 0.020 |
Why?
| Drug Resistance, Bacterial | 1 | 2009 | 176 | 0.020 |
Why?
| Cell Line | 1 | 2014 | 2781 | 0.020 |
Why?
| Total Quality Management | 1 | 2008 | 60 | 0.020 |
Why?
| Ventilator Weaning | 1 | 2008 | 37 | 0.020 |
Why?
| Precision Medicine | 1 | 2012 | 387 | 0.020 |
Why?
| Microbial Sensitivity Tests | 1 | 2009 | 352 | 0.020 |
Why?
| Placebos | 1 | 2008 | 201 | 0.020 |
Why?
| Neutrophil Infiltration | 1 | 2008 | 105 | 0.020 |
Why?
| Capillary Permeability | 1 | 2008 | 139 | 0.020 |
Why?
| United States Food and Drug Administration | 1 | 2008 | 204 | 0.020 |
Why?
| Health Plan Implementation | 1 | 2008 | 137 | 0.020 |
Why?
| Interdisciplinary Communication | 1 | 2008 | 186 | 0.020 |
Why?
| Drug Industry | 1 | 2008 | 106 | 0.020 |
Why?
| Chemokines | 1 | 2008 | 226 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2012 | 1198 | 0.020 |
Why?
| Acid-Base Equilibrium | 1 | 2007 | 27 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2011 | 2012 | 0.020 |
Why?
| Cost Control | 1 | 2006 | 39 | 0.020 |
Why?
| Umbilical Veins | 1 | 2006 | 61 | 0.020 |
Why?
| Medical Audit | 1 | 2007 | 77 | 0.020 |
Why?
| Ketones | 1 | 2007 | 47 | 0.020 |
Why?
| CD8 Antigens | 1 | 2006 | 76 | 0.020 |
Why?
| Microcirculation | 1 | 2007 | 145 | 0.020 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 107 | 0.020 |
Why?
| CD4 Antigens | 1 | 2006 | 138 | 0.020 |
Why?
| Bacillus subtilis | 1 | 2006 | 65 | 0.020 |
Why?
| Information Management | 1 | 2006 | 15 | 0.020 |
Why?
| Cell Count | 1 | 2006 | 314 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2006 | 376 | 0.020 |
Why?
| Genome-Wide Association Study | 1 | 2012 | 1333 | 0.010 |
Why?
| User-Computer Interface | 1 | 2006 | 148 | 0.010 |
Why?
| Interleukin-10 | 1 | 2006 | 304 | 0.010 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2007 | 253 | 0.010 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2012 | 2073 | 0.010 |
Why?
| Inflammation Mediators | 1 | 2006 | 505 | 0.010 |
Why?
| Asthma | 1 | 2017 | 2230 | 0.010 |
Why?
| Hypoglycemia | 1 | 2007 | 427 | 0.010 |
Why?
| Endothelium, Vascular | 1 | 2007 | 901 | 0.010 |
Why?
| Cardiotonic Agents | 1 | 2001 | 126 | 0.010 |
Why?
| Hypothermia, Induced | 1 | 2001 | 76 | 0.010 |
Why?
| RNA, Messenger | 1 | 2006 | 2708 | 0.010 |
Why?
| Mass Screening | 1 | 2006 | 1149 | 0.010 |
Why?
| Dopamine | 1 | 2001 | 289 | 0.010 |
Why?
| Hypoglycemic Agents | 1 | 2007 | 1220 | 0.010 |
Why?
| Anti-Inflammatory Agents | 1 | 2001 | 480 | 0.010 |
Why?
| Insulin | 1 | 2007 | 2326 | 0.010 |
Why?
|
|
Douglas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|